Navigation Links
Hormone therapy increases frequency of abnormal mammograms, breast biopsies

Combined hormone therapy appears to increase the risk that women will have abnormal mammograms and breast biopsies and may decrease the effectiveness of both methods for detecting breast cancer, according to a report in the February 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Hormone therapy use remains common among women beginning menopause, according to background information in the article. For women with a uterus considering combined estrogen plus progestin use, identified breast cancer issues represent a concern, the authors write.

Rowan T. Chlebowski, M.D., Ph.D., of the Los Angeles Biomedical Research Institute at HarborUCLA Medical Center, and colleagues studied 16,608 post-menopausal women who participated in the Womens Health Initiative (WHI) clinical trial, beginning in 1993 through 1998. A total of 8,506 women were randomly assigned to receive a combination of estrogen (0.625 milligrams of conjugated equine estrogens per day) plus progesterone (2.5 milligrams of medroxyprogesterone acetate per day), while 8,102 took a placebo. Each woman received a mammogram and breast examination yearly, with biopsies performed based on physicians clinical judgment.

During the 5.6 years of the study, 199 women in the combined hormone group and 150 women in the placebo group developed breast cancer. Mammograms with abnormal results were more common among women taking hormones than among women taking placebo (35 percent vs. 23 percent); women taking hormones had a 4 percent greater risk of having a mammogram with abnormalities after one year and an 11 percent greater risk after five years.

Breast biopsies also were more common among women taking hormones than among those assigned to placebo (10 percent vs. 6.1 percent). Although breast cancers were significantly increased and were diagnosed at higher stages in the combined hormone group, biopsies in that group less frequently diagnosed cancer (14.8 percent vs. 19.6 percent), the authors write.

After discontinuation of combined hormone therapy, its adverse effect on mammograms modulated but remained significantly different from that of placebo for at least 12 months, they continue.

Use of combined hormones increases breast density, which increases the risk of breast cancer and may also delay diagnosis, the authors note. However, breast density was not measured in the current study.

Use of conjugated equine estrogens plus medroxyprogesterone acetate for approximately five years resulted in more than one in 10 and one in 25 women having otherwise avoidable mammogram abnormalities and breast biopsies, respectively, and compromised the diagnostic performance of both, the authors conclude. This adverse effect on breast cancer detection should be incorporated into risk-benefit discussions with women considering even short-term combined hormone therapy.


Contact: Laura Mecoy
JAMA and Archives Journals

Related medicine news :

1. LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies
2. Hormone refractory prostate cancers more likely to spread to other organs
3. Newly discovered role of thyroid hormone during pregnancy
4. Stress hormone impacts memory, learning in diabetic rodents
5. Moving beyond tamoxifen: Drug discovery and the future of selective hormone receptor modulators
6. Diabetes, Growth Disorders Drive Sales of Pediatric Hormone Drugs
7. Sex Hormones Dont Seem to Affect Prostate Cancer Risk
8. Hormone Therapy Only Helps Some Older Men With Prostate Cancer
9. FDA Warns Against Bio-Identical Hormone Therapy
10. FDA Asserts New Policy to Restrict Womens Access to Bioidentical Hormones
11. Just 4 months of hormone therapy can delay prostate cancer growth by up to 8 years
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has released ... Surviving Mesothelioma has just posted the findings on the website. Click here to ... cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. ...
(Date:11/27/2015)... ... 27, 2015 , ... The print component of “Supporting Our ... Dallas, New York, Minneapolis, South Florida, with a circulation of approximately 250,000 copies ... a vast social media strategy and across a network of top news sites ...
(Date:11/27/2015)... DE (PRWEB) , ... November 27, 2015 , ... ... member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s ... an independent group of Microsoft Dynamics SL software users, partners, industry experts and ...
(Date:11/27/2015)... , ... November 27, 2015 , ... CBD College ... of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. ... accredited colleges, as only one of twelve colleges and universities in the state of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and distributor ... Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , ... up-to-date with a version of Asterisk that will receive not only security fixes, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Japanese Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
Breaking Medicine Technology: